FDA sets May 1 deadline for UniQure's Huntington's gene therapy; Inovio's Voceryq approved for RRP; AbbVie wins Botox IRA ...
AbbVie licenses two preclinical migraine programs from China’s Brise Pharmaceuticals in a $757M deal that dates back to 2024.
Fresenius gets exclusive options on up to 37 WuXi Biologics biosimilar candidates, potentially more than doubling its 29-molecule portfolio.
Karyopharm files for Chapter 11 and plans a merger with Gamida Cell parent Ayrmid, backed by $55M in DIP financing; shares fall 84%.
Regulators issued the hold for Bright Minds' BMB-101 after identifying toxicity issues in preclinical mouse models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results